Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Phase 1 Study Assessing the Safety, Immunogenicity and Dose Response of IC84, a New Vaccine Against Clostridium Difficile, in Healthy Subjects

NCT01296386 is registered in ClinicalTrials.gov with Valneva Austria GmbH as lead sponsor.

NCT NCT01296386
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01296386 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Phase 1 Study Assessing the Safety, Immunogenicity and Dose Response of IC84, a New Vaccine Against Clostridium Difficile, in Healthy Subjects
Lead sponsor
Valneva Austria GmbH
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2010
Completion date
April 30, 2013
Enrollment
82 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

clostridium difficile infection